Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 PH6 versus AMINOSYN II 10 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 8 5 PH6 versus AMINOSYN II 10 W ELECTROLYTES.
AMINOSYN 8.5% (PH6) vs AMINOSYN II 10% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% (pH 6) provides a mixture of essential and nonessential amino acids for protein synthesis and nitrogen balance maintenance in patients unable to tolerate oral or enteral nutrition.
Amino acids serve as substrates for protein synthesis and nitrogen balance; electrolytes maintain osmotic and acid-base balance.
1-1.5 g amino acids/kg/day intravenously, typically 500 mL of a 8.5% solution (42.5 g amino acids) infused over 8-24 hours.
1-2 g/kg/day (0.1-0.2 g/kg/hour) IV via central line as continuous infusion.
None Documented
None Documented
Not applicable as a fixed value; elimination half-life of individual amino acids varies (minutes to hours) and is dependent on metabolic demand and renal function.
The terminal elimination half-life of individual amino acids varies but is generally short (range 0.5–2 hours) due to rapid uptake and metabolism. Clinically, the half-life of infused amino acids is not a relevant parameter for dosing; rather, infusion rate is adjusted to maintain nitrogen balance.
Primarily renal; elimination depends on metabolic utilization. Unused amino acids are deaminated and excreted as urea in urine (over 90%). Fecal elimination is negligible.
Amino acids are primarily metabolized to urea and other nitrogenous waste products, which are excreted renally (90-95% of total nitrogen excreted as urea). Unmetabolized amino acids in plasma are also filtered and reabsorbed by the kidneys; negligible amounts are excreted unchanged (<5%). Biliary/fecal excretion is minimal (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution